CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- DeepHealth, a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered radiology and health informatics, today announces a data and AI development partnership with HOPPR (www.hoppr.ai). This collaboration will commercialize a pioneering Medical-Grade Generalized Foundational Model and foster the development of Fine-Tuned models for breast, prostate, and lung cancer detection, leveraging generative medical imagingfocused AI ...

LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, 2024 at 11:30 a.m. Eastern Time. There will be simultaneous and archived w ...

I I F ■ F Matteo Colombo Investment update Since my June publication on RadNet, Inc. (NASDAQ:RDNT) reiterating it a buy the stock is +10% and we observed another set of strong quarterly numbers in its Q2 FY'24 earnings. Here I'll run through my analysis of the quarter, updated modelling, and reinstated my next price objective to $72 per share, still eyeing long-term objectives of $95 per share in the base case. Figure 1. Tradingview RDNT is clear evidence that the market pays very close attention to how bus ...

For the quarter ended June 2024, RadNet (RDNT) reported revenue of $459.71 million, up 13.9% over the same period last year. EPS came in at $0.16, compared to $0.24 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $437.32 million, representing a surprise of +5.12%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.16. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

Group 1: Earnings Performance - RadNet reported quarterly earnings of $0.16 per share, matching the Zacks Consensus Estimate, but down from $0.24 per share a year ago [1] - The company posted revenues of $459.71 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 5.12% and up from $403.72 million year-over-year [2] - Over the last four quarters, RadNet has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - RadNet shares have increased approximately 71% since the beginning of the year, significantly outperforming the S&P 500's gain of 9.9% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.16 for the coming quarter and $0.58 for the current fiscal year [4][7] - The estimate revisions trend for RadNet is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Outpatient and Home Healthcare industry, to which RadNet belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact RadNet's stock performance [5]

Total Company Revenue increased 13.9% to $459.7 million in the second quarter of 2024 from $403.7 million in the second quarter of 2023; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 36.4% to $15.8 million in the second quarter of 2024 from $11.6 million in the second quarter of 2023 Digital Health Revenue growth resulted in part from a $3.2 million (or 136.6%) increase in AI Revenue, which climbed to $5.6 million during the second quarter of 2024 from $2.4 ...

RadNet, Inc. (RDNT) is set to release results for the second quarter of 2024 on Aug 8 before the opening bell. For the second quarter of 2024, the Zacks Consensus Estimate for RadNet's revenues is pegged at $437.3 million, an increase of 8.3% from the year-ago reported figure. Estimates for RadNet's Q2 earnings have remained unchanged at 16 cents per share in the past 30 days. On the first-quarter earnings call, management stated that the segment's revenues were boosted by improved reimbursements from comme ...

Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1680804&tp_key=197206db18. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10191154. About RadNet, Inc. RadNet, Inc., is the leading nation ...

Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1680804&tp_key=197206db18. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10191154. CONTACTS: LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) ...

HB 1259 expands breast and lung cancer screening coverage. Since January 1, 2024, Maryland-regulated insurers have been prohibited from imposing a copayment, coinsurance, or deductible on coverage for diagnostic mammograms, breast ultrasound, or breast Magnetic Resonance Imaging (MRI) for the detection and diagnosis of breast cancer. This has made imaging more accessible and affordable to patients in Maryland. The new bill now expands that legislation to include image-guided breast biopsy. Additionally, und ...